COVID-19 layered on top of Brexit have created unique challenges and opportunities in the EU and UK medtech regulatory markets. Elemed’s Elena Kyria offers advice to help jobseekers and recruiters navigate the current turbulent waters and beyond.
When it comes to recruiting regulatory experts in the EU, timing is crucial, especially with the mountain of work needing to be done in the context of the new Medical Device and IVD Regulations.
But both Brexit and the COVID-19 pandemic have disrupted hiring timeframes, logistics, and travel, so companies are finding that the time it takes to hire is much longer
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.
FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.
